Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors

The pharmacophore model of arylpiperazine amide derivatives was built using Discovery Studio 2.0 software package and the best pharmacophore model (Hypo 1) was validated by Enrichment and ROC method (EF at 2%, 5% and 10% are 30.6, 12.2 and 7.7; AUC of the ROC curve is 0.93). According to the best pharmacophore model, 11 N-phenyl-1-arylamide, N-phenylbenzenesulfonamide derivatives, compounds 26–28, and 33a–g, were designed to be synthesized and their BACE 1 inhibitory activities were determined experimentally. Their theoretical results were in good agreement with the experimental values. Compound 33d, which displayed the highest BACE 1 activity (18.33 ± 2.80 μmol/L) among these two series, was chosen to study the protein binding pattern and the result showed that it was in close contact with two essential catalytic aspartates (Asp32 and Asp228) of the BACE 1.

The pharmacophore model of arylpiperazine amide derivatives was built and the validation of the Hypo 1 was ascertained. Eleven N-phenyl-1-arylamide, N-phenylbenzenesulfonamide derivatives 26–28, 33a–g were selected, synthesized and tested the BACE 1 inhibitory activities.Figure optionsDownload as PowerPoint slide